Is MRD Negativity the Goal of Myeloma Treatment?

Using MRD negativity to measure depth of response & to discontinue treatment in multiple myelomaПодробнее

Advancements in Myeloma | What progress towards a cure and prevention has been made?Подробнее

Is MRD Negativity the End Goal? Understanding When/Why It's ImportantПодробнее

Update in Multiple MyelomaПодробнее

Is CAR T-cell therapy being used to treat newly diagnosed multiple myeloma?Подробнее

Future Directions for Novel and Next Generation Therapy in Multiple Myeloma | Dana-FarberПодробнее

Kenneth C. Anderson - Multiple myeloma cured in 2030: what are the next steps?Подробнее

ASH23: CARTITUDE-2 Trial on Ciltacabtagene Autoleucel in Multiple Myeloma | Jens Hillengass, MD, PhDПодробнее

Hitting the BCMA Target in Multiple MyelomaПодробнее

Using MRD Status as an Endpoint for Drug Approval with Dr. Manni MohyuddinПодробнее

Should cure be the goal for multiple myeloma?Подробнее

Newly Diagnosed Multiple Myeloma | Diagnosis, Initial Treatment | ASCT, Maintenance Therapy, GoalsПодробнее

Approaching MRD in Multiple MyelomaПодробнее

MRD2STOP: Can multimodal MRD negativity guide discontinuation of maintenance treatment in myeloma?Подробнее

Measurable Residual Disease (MRD) in AML and ALLПодробнее

Identifying and treating high-risk/MRD positive newly diagnosed multiple myelomaПодробнее

What does it mean when a myeloma patient is MRD negative?Подробнее

DARA+RVd in Pts w/Transplant Eligible Newly Diagnosed Multiple Myeloma after 24 Months MaintenanceПодробнее

Sustained MRD negativity in multiple myelomaПодробнее